0.68 - 0.75
0.33 - 0.86
12.91M / 4.66M (Avg.)
35.00 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-29.45%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-61.53%
Negative gross profit growth while 3606.HK is at 2.03%. Joel Greenblatt would examine cost competitiveness or demand decline.
-496.72%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-496.72%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-64.24%
Negative net income growth while 3606.HK stands at 9.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-27.12%
Negative EPS growth while 3606.HK is at 11.11%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-27.12%
Negative diluted EPS growth while 3606.HK is at 11.11%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
29.22%
Slight or no buybacks while 3606.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
29.28%
Diluted share change of 29.28% while 3606.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-9.10%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-2.79%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-48.70%
Negative 10Y revenue/share CAGR while 3606.HK stands at 45.73%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-49.30%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-53.69%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-963.10%
Negative 10Y OCF/share CAGR while 3606.HK stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-956.34%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-34.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-208.22%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-514.36%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-282.74%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
135.21%
10Y equity/share CAGR at 50-75% of 3606.HK's 228.15%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
-6.80%
Negative 5Y equity/share growth while 3606.HK is at 8.30%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-26.90%
Negative 3Y equity/share growth while 3606.HK is at 15.56%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-5.13%
Firm’s AR is declining while 3606.HK shows 19.78%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
22.07%
Inventory growth well above 3606.HK's 3.03%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
9.37%
Asset growth above 1.5x 3606.HK's 3.71%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-26.90%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
73.53%
Debt growth far above 3606.HK's 7.87%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-37.45%
Our R&D shrinks while 3606.HK invests at 18.11%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-33.04%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.